Implantation of a medical device, i.e. a biomaterial  into human tissue is inevitably associated with adverse reactions against the non-self biomaterial. Whether the device will be accepted by the host is determined by the biocompatibility, defined as the ability of the material to perform with an appropriate host response in a specific application. Our ambition is to dissect mechanisms of inflammation and thrombosis in response to biomaterial exposure. This will aid in solving critical markers in biomaterials treatment, such as inflammation in hemodialysis, thrombosis associated with mechanical heart support and challenges related to in vivo administration of nanopharmaceuticals.